arrow
S

Se Hoon Park

Bowen University Teaching Hospital
H指数:72
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey

全球范围内肾细胞癌系统性治疗的可及性与报销差异:国际ARON-AID调查结果

2026-10-060
OAAI
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

与毒性相关的免疫治疗停药及结局:接受基于免疫联合治疗方案的晚期肾细胞癌患者(ARON-1研究)

2025-11-040
PRE
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04研究的通俗语言摘要:沙西妥珠单抗在铂类化疗和免疫疗法之后,用于患有膀胱、尿道或上尿路局部晚期或转移性癌症的人群

2025-11-011
PRE
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

ctDNA指导下的辅助阿特珠单抗治疗在肌肉浸润性膀胱癌中的应用

2025-10-0110
PRE
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer

KEYLYNK-010研究中患者报告结局:帕博利珠单抗联合奥拉帕利与阿比特龙或恩扎卢胺治疗生物标志物未筛选、既往接受过治疗的转移性去势抵抗性前列腺癌患者

2025-07-190
OAAI
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease

阿维鲁姆单抗一线维持治疗晚期尿路上皮癌:来自JAVELIN Bladder 100试验中非内脏或仅淋巴结疾病患者的长期结局

2025-06-030
OAAI
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial☆

恩诺单抗维多汀联合帕博利珠单抗治疗未经治疗的局部晚期或转移性尿路上皮癌:III期EV-302/KEYNOTE-A39试验的中位2.5年随访结果☆

2025-06-010
PREAI
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

帕博利珠单抗联合仑伐替尼在转移性肾细胞癌患者中的应用:国际ARON-1研究的真实世界证据

2025-05-090
OA
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial

Avelumab一线维持治疗晚期尿路上皮癌:来自JAVELIN Bladder 100试验的患者报告结局和症状或毒性调整时间的长期分析

2025-05-020
OAAI
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
2025-02-200
OAAI
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Sacituzumab govitecan在晚期尿路上皮癌中的应用:TROPiCS-04,一项III期随机试验

2025-02-014
PRE
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

lenvatinib联合pembrolizumab与舒尼替尼治疗的肾细胞癌患者基线转移的临床结果: CLEAR试验的事后分析

2024-12-300
OA